- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
EMBC
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Embecta Corp · Healthcare · Medical Instruments & Supplies
Latest close
3.64 USD
10.6%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -48.4% below the Trend Line and sits at 7.1% of its 52-week range. The latest completed week returned 10.6%, after a 8.7% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 33/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.
Setup score
24
out of 100
Latest Close
3.64 USD
31 Jul 2026
1W Return
10.6%
latest completed week
4W Return
8.7%
short-term follow-through
12W Return
0.3%
quarterly tape
Trend Breadth
26.9%
14 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
10.6%
Latest completed week; four-week move 8.7%.
Indicator stack
15/40
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 43.11%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
53/100 conviction; expected move 57.2%.
News sentiment
33/100
59 relevant articles in the latest sentiment read.
Event risk
4d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -48.4% below the Trend Line and sits at 7.1% of its 52-week range. The latest completed week returned 10.6%, after a 8.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0612-week average 0.03
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 8.7% over four weeks, 0.3% over 12 weeks, and -61.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year14
Trend breadth26.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.72Latest activity-pressure read.
Pressure change37.5%Four-week change in activity pressure.
Leadership-66.34Latest relative-leadership reading.
RS change7.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is inexpensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 90%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength87/100Blend of value, momentum, and quality. Underlying universe rank 14; rank 1 is best.
Value97/100Relative valuation strength. Underlying universe rank 4; rank 1 is best.
Quality90/100Profitability and accounting quality. Underlying universe rank 11; rank 1 is best.
Momentum2/100Medium-term price momentum. Underlying universe rank 99; rank 1 is best.
Growth17/100Revenue and earnings growth. Underlying universe rank 84; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework96/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 1.7x Price divided by trailing earnings.
- Price / sales
- 0.2x Market value relative to trailing revenue.
- EV / EBITDA
- 4.2x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 16.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 62.5% Gross profit retained from each unit of revenue.
- Operating margin
- 25.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 21.3% Free cash flow generated from revenue.
- Return on invested capital
- 32.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -3.4% Latest one-year revenue growth.
- EPS growth
- 114.8% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 256.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 14.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 14.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 3.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
EMBC shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 57.2%, and Sharemaestro trend signal inactive.
Conviction53/100
Expected move57.2%
Put/call volume0.00
Insider activity1 / 0
1 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment33/100
Weighted news tone is negative across 59 relevant articles.
1 positive · 24 neutral · 34 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move57.2%Nearest-chain priced movement where available.
52-week drawdown-75.9%Distance below the 52-week high.
13-week volatility17.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher13 of 2611 weeks finished lower.
Best week+12.2%Week of 26 Jun.
Worst week-60.6%Week of 8 May.
Latest week+10.6%Week of 31 Jul.
Shape of recent returns
Strong gains5
Modest gains8
Flat weeks2
Modest losses4
Sharp losses7
Recent vol17.5%13-week weekly-return volatility.
Base vol10.7%52-week weekly-return volatility.
Up/down split28/22Count of positive and negative weeks in the 52-week window.
Average skew4.7% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Medical Instruments & Supplies
4-week rank14 / 50
Group average-0.7%
Trend breadth40.0%
Trend40.0%active weekly trend signals
MD74.0%positive activity pressure
RS36.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape18/100
Trend, activity pressure, participation, and risk combine to a 18/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.06; No reversal markers Next-Week ExpectancyNegative 43.11%Next-week expectancy is negative with a 43.11% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors71/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Tiny Titans rank 88; Buyback Yield rank 56; Small Cap Core rank 3 SVQF96/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 26.5 of 726 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options36/100EMBC shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.00, expected move of 57.2%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 57.2% Sentiment33/100Weighted news tone is negative across 59 relevant articles.
Embecta (EMBC) Stock Drop: Robbins LLP Reminds Investors of Class Action and Urges Shareholders Who Lost Money to Contact the Firm Insiders1 / 01 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 3.64 USD | 10.6% | 7.05 USD | 12.14 USD | -0.72 | -66.34 | 5.3M | Off |
| 24 Jul 2026 | 3.29 USD | 1.2% | 7.32 USD | 12.24 USD | -0.86 | -69.85 | 5.7M | Off |
| 17 Jul 2026 | 3.25 USD | 0.3% | 7.60 USD | 12.34 USD | -0.90 | -71.22 | 6.4M | Off |
| 10 Jul 2026 | 3.24 USD | -3.3% | 7.88 USD | 12.43 USD | -1.00 | -72.89 | 8.1M | Off |
| 3 Jul 2026 | 3.35 USD | -4.0% | 8.15 USD | 12.53 USD | -1.16 | -71.91 | 8.1M | Off |
| 26 Jun 2026 | 3.49 USD | 12.2% | 8.43 USD | 12.63 USD | -1.30 | -70.93 | 13.9M | Off |
| 19 Jun 2026 | 3.11 USD | 0.3% | 8.72 USD | 12.73 USD | -1.48 | -75.59 | 17.5M | Off |
| 12 Jun 2026 | 3.10 USD | -8.3% | 9.09 USD | 12.84 USD | -1.56 | -75.39 | 8.5M | Off |
| 5 Jun 2026 | 3.38 USD | 0.0% | 9.46 USD | 12.97 USD | -1.53 | -72.94 | 8.4M | Off |
| 29 May 2026 | 3.38 USD | 2.1% | 9.79 USD | 13.09 USD | -1.49 | -74.52 | 6.7M | Off |
| 22 May 2026 | 3.31 USD | 5.7% | 10.11 USD | 13.22 USD | -1.07 | -74.73 | 13.7M | Off |
| 15 May 2026 | 3.13 USD | -13.7% | 10.46 USD | 13.35 USD | -0.91 | -76.20 | 19.2M | Off |
| 8 May 2026 | 3.63 USD | -60.6% | 10.80 USD | 13.49 USD | -0.82 | -72.99 | 37.7M | Off |
| 1 May 2026 | 9.20 USD | 0.1% | 11.11 USD | 13.64 USD | -0.85 | -29.05 | 4.1M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.